Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 juil. 2026 08h32 HE | Source: SciSparc Ltd

SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company

TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage...
28 juil. 2026 00h30 HE | Source: Custom Market Insights

Global Pharmaceutical Surfactants Market Size/Share Worth USD 6.93 Billion by 2035 at a 4.42% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

AUSTIN, TX, USA, July 28, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Pharmaceutical Surfactants Market Size, Trends and Insights By Type (Non-ionic...
27 juil. 2026 08h25 HE | Source: SciSparc Ltd

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its board of directors has made a decision to target the agentic...
24 juil. 2026 10h04 HE | Source: BCC Research LLC

AI-Powered Wound Care Market Poised for Revolutionary Disruption as Investment Activity Surges

AI is transforming biologic wound care through earlier diagnosis, better healing predictions, improved therapy selection, and faster clinical research.
23 juil. 2026 00h10 HE | Source: Clinuvel Pharmaceuticals Limited

CLINUVEL implements strategic reorganisation to refocus on U.S. markets

MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and...
22 juil. 2026 14h00 HE | Source: Custom Market Insights

[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 22, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Botulinum Toxin in Urology Market Size, Trends and Insights By Product Type...
22 juil. 2026 12h05 HE | Source: JP 3E Holdings Inc.

Vivasor Appoints JP3E Development Corp. (JP 3E Holdings, Inc. (JPTE) Majority Owned Subsidiary) as Exclusive Strategic Representative in the Republic of Korea

Vivasor Appoints JP3E Development as Exclusive Strategic Representative in the Republic of Korea
21 juil. 2026 17h00 HE | Source: Custom Market Insights

[Latest] Global AI in Drug Repurposing Market Size/Share Worth USD 10.56 Billion by 2035 at a 23.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 22, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “AI in Drug Repurposing Market Size, Trends and Insights By Component (Software...
21 juil. 2026 13h30 HE | Source: BCC Research LLC

Substance Use Disorder Treatment Market to Reach $14.6 Billion by 2030, Driven by Growing Patient Populations and Policy Reform

Analyzes market dynamics, competitive developments, patent and regional opportunities shaping the future of substance use disorder treatment worldwide.
16 juil. 2026 04h58 HE | Source: Arletta Pharma Solutions

Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US

FDA endorses key elements of Arletta Pharma's Phase 2 study of Lybrido, a dual-action therapy for women with FSIAD/HSDD, and opens path to a single Phase 3

Page suivante